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http:WHAT THIS PAPER ADDS
This single-centre retrospective study demonstrates that young patients with abdominal aortic aneurysms have
signiﬁcant comorbidities and do not necessarily have a long life expectancy. It would be therefore reasonable to
offer endovascular repair to this subgroup of patients.Objectives: To compare the mid-term outcome and secondary intervention rate following elective open and
endovascular aortic aneurysm repair (EVAR) in patients aged 65 years and younger.
Methods: A retrospective analysis of patients aged 65 years and younger who had elective abdominal aortic
aneurysm repair (AAA) between 1994 and 2012.
Results: One hundred and sixty-ﬁve patients under the age of 65 years (mean age: 61 years  4; 8 women) had
elective abdominal aneurysm repair (97 EVAR and 68 open). The overall 30-day mortality rate was 3.7% (2.1%
EVAR and 5.9% open). Forty per cent of patients had died at a median follow up of 77 months (interquartile
range, 36e140). Most deaths were not related to aneurysm. There was no difference in the long-term mortality
between the EVAR and open groups (hazard ratio [HR] ¼ 1.22; 95% conﬁdence interval [CI] 0.75e1.98, p ¼ .43),
but there was a trend of better outcomes with the use of commercially made endografts over open repair
(HR ¼ 2.9; 95% CI 0.9e10.0, p ¼ .08) and custom-made endografts (HR ¼ 3.1, 95% CI 0.9e10.3; p ¼ .07). Eleven
per cent of patients who had EVAR required a further procedure compared with 13% who had open repair. All
but one of the re-interventions in the EVAR group was performed on patients who had custom-made
endografts.
Conclusions: Young patients with AAA have signiﬁcant comorbidities and do not necessarily have long lifespans.
In the less ﬁt younger patients with AAA, the results with EVAR are comparable with ﬁt patients who had open
AAA repair. The management of ﬁtter young patients with AAA remains controversial, but improving results with
EVAR over time may increase the role of EVAR in this group.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Randomised studies have demonstrated beneﬁt from
endovascular aneurysm repair (EVAR) when compared with
open repair of abdominal aortic aneurysms (AAAs).1e3 The
EVAR1 trial demonstrated a short-term beneﬁt for older
patients who had EVAR.4 The long-term beneﬁt is similar for
both procedures.4
Open repair is the treatment of choice in young patients.
Uncertainties about long-term outcomes,4 re-intervention,
and late ruptures5 have discouraged the use of EVAR in
younger patients who may have a long life expectancy. The
introduction of a United Kingdom national AAA screening
program will result in a small, but signiﬁcant, increase in the
treatment of younger patients.6 The National Surgicalrresponding author. N. Altaf, Department of Vascular and Endovas-
urgery, Queens Medical Centre, Nottingham NG7 2UH, United
m.
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//dx.doi.org/10.1016/j.ejvs.2013.04.027Quality Improvement Program suggested similar perioper-
ative outcomes after open repair and EVAR in young
patients.7
The aim of this study was to compare the mid-term
outcome and re-intervention rates in patients aged 65
years and under who had EVAR or open repair of an AAA.METHODS
Patient group
All patients, aged 65 years and under, who had elective AAA
repair of an infrarenal non-ruptured abdominal aortic
aneurysm (AAA) >5.5 cm between January 1994 and
February 2011 were identiﬁed from theatre records and a
prospectively collected database of all patients who had
EVAR at the Queen’s Medical Centre, Nottingham, United
Kingdom.
Data on comorbidities, the operation, and clinical out-
comes were obtained from the prospective database for
endovascular interventions, a review of the patients’ hospital
records, general practitioner records, and death certiﬁcates.
316 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 3 September/2013All EVARs were performed in a vascular surgical theatre
using a mobile image intensiﬁer. Custom-made Nottingham
grafts were used in 57 patients (18 bifurcated, 39 aorto-uni-
iliac with femefem crossover). The aorto-uni-iliac graft
consisted of a commercially available Dacron graft tailored
to ﬁt the patient’s anatomy with a variable number of
stents within it with a contralateral occlusion device and a
femefem crossover.8 The bifurcated system was described
as per Chuter et al.9
In this unit, commercially-made grafts have been slowly
introduced since 2001. From 2002 onwards, commercially-
made grafts were used in this study group of patients.
Zenith (Cook) grafts were used in 38 patients (36
bifurcatedd13 Trifab and 23 Flex; 2 Flex aorto-uni-iliac) and
two bifurcated Medtronic (Talent) grafts were used. Post-
operative care was in a high-dependency unit or in a ward.
Open repair was performed using either tube grafts or
bifurcated Dacron grafts. Patients were transferred to
intensive care or high-dependency units postoperatively.Follow-up protocol
Postoperative management of EVAR patients consisted of a
post-operative computed tomography (CT) scan followed by
annual Duplex scans and abdominal X-rays, with the
exception of those patients who participated in EVAR1 who
had annual CT scans. Secondary interventions, complica-
tions, and cause of death were recorded. The general
practices of patients who had moved away from the local
area were contacted about re-admission rates and whether
they were aneurysm related. The units in which patients
were followed up elsewhere (n ¼ 19) were contacted to
review the re-intervention rates. However, we were unable
to obtain information on re-intervention rates in 14
patients.
Patients who had open repair were seen in the outpa-
tient clinic once and then, if well, were discharged from
further follow up. Some patients continued to be followed
up as part of the EVAR 1 study protocol.Table 1. Differences in risk factors in outcomes in patients operat
aneurysm repair (EVAR) and open repair.
Open AAA
(n ¼ 68)
Cu
(n
Age, years
(median þ IQR)
63 (60e64) 62
IHD (%) 39 80
Hypertension (%) 50 53
Smoking (%) 44 67
DM (%) 7 4
Renal impairment
(CKD > 3)
3 35
COPD (%) 10 46
30-day mortality (%) 5.9 3.5
Follow-up (median months þ IQR) 89 (50e141) 124
Long-term mortality (%) 47 52.
Note. With respect to the open AAA risk factors data, information wa
IQR ¼ interquartile range; IHD ¼ ischaemic heart disease; DM ¼ di
obstructive pulmonary disease.*p < .05.Statistical analysis
Data management and statistical analysis were performed
using SPSS 20.0 software (SPSS, Chicago, IL, USA). The basic
demographics and risk factors were compared between the
EVAR and open group using the ManneWhitney U test and
the chi-square tests for continuous and categorical variables
respectively.
Cox regression analysis and KaplaneMeier plots were
performed to analyse the association between the type of
procedure and mortality.
RESULTS
Basic demographics and outcomes
During the study period, 1,900 patients had AAA repair. Of
these, 165 were younger than 65 years old (8 women, mean
age 61 years, SD 4 years). The median follow up was 77
months (interquartile range, 36e140 months).
The combined 30-day mortality of the 165 patients (open
AAA: n ¼ 68; custom-made EVAR: n ¼ 57; commercially
available EVAR: n ¼ 40) was 3.7% (n ¼ 6). The basic de-
mographics are shown in Table 1. The open AAA repair 30-
day mortality was 5.9% (n ¼ 4). The 30-day mortality for the
EVAR group was 2.1% (n ¼ 2), with two deaths occurring
postoperativelydone in 1995 and one in 1999 (both had
custom-made devices). One patient had an open conversion
of the EVAR intraoperatively and died. Another died 25 days
after the EVAR with biliary sepsis.
Information was available about long-term outcomes in
164 of the 165 patients. Some 65 patients had died (40%) in
the median 6.5-year follow up.
Long-term EVAR mortality
In the EVAR group, there were 33 (34%) deaths, of which
18% (n ¼ 6) were AAA related, 9% (n ¼ 3) were unknown,
and 73% (n ¼ 24) was not related to AAA repair. The AAA
unrelated deaths include eight cardiac deaths, seven cancer
deaths, and nine miscellaneous deaths.ed using custom-made and commercially-available endovascular
stom-made EVAR
¼ 57)
Commercially available
EVAR (n ¼ 40)
p
(59e64) 63 (61e65) 0.2
45 <0.05
78 <0.05
85 <0.05
25 <0.05
3 <0.05
43 <0.05
0 0.3
(55e166) 44 (18e70) <0.05
6 7.5 <0.05
s not available in 7 patients. AAA ¼ abdominal aortic aneurysm;
abetes mellitus; CKD ¼ chronic kidney disease; COPD ¼ chronic
N. Altaf et al. 317Six of the 33 deaths after EVAR were related to the AAA
repair (18%). All of these occurred in patients who had the
early custom-made grafts (6/57; 11%) There were no AAA-
related deaths in patients who had the commercially-made
stent grafts. There was one intraoperative conversion (as
mentioned above). One patient had an enlarging sac with a
type II endoleak from a lumbar artery, which was embol-
ised. The patient then had a type II endoleak from a
circumﬂex iliac artery, which, despite an attempt, could not
be treated by embolisation. The patient died from an aortic
rupture 14 years after the initial procedure.
One patient underwent a laparotomy to repair a pseu-
doaneurysm at the top end of the graft 8 years after the
initial EVAR. The patient died postoperatively. Two patients
had open revisions for migration of the graft 10 and 3 years,
respectively, after the initial EVAR. Both died in the peri-
operative period.
A sixth patient presented 3 months after an EVAR with
bilateral ischaemic legs and an occluded EVAR stent graft.
He was too frail to undergo any further intervention and
died from his ischaemic legs.Long-term open repair mortality
In the open group there were 32 (47%) deaths in the long
term follow-up period. Four were AAA related deaths within
30 days of the operation. All four were from multi-organ
failure. Twenty-three (72%) deaths were non-AAA related,
of which nine were cardiac related, ten were cancer related,
and four were miscellaneous causes. The cause was not
known in ﬁve patients (16%).Outcomes between EVAR and open AAA repair
There was no difference in death rates between the EVAR
and open repair groups (hazard ratio [HR] ¼ 1.22; 95%
conﬁdence interval [CI] 0.75e1.98, p ¼ .43) (Fig. 1). There
was also no difference in the death rates between thoseFigure 1. KaplaneMeier survival analysis demonstrating cumula-
tive survival in the endovascular aneurysm repair (EVAR) and open
abdominal aortic aneurysm repair groups.who underwent open repair and custom-made EVAR
(HR ¼ 1.04; 95% CI 0.6e1.7, p ¼ .9; Fig. 2).
There was a trend for improved long-term death rates
with commercially-available grafts over open AAA repair
(HR ¼ 2.9; 95% CI 0.9e10.0, p ¼ .08), as well as
commercially-available EVAR over custom-made EVAR
(HR ¼ 3.1, 95% CI 0.9e10.3; p ¼ .07). However, these were
statistically not signiﬁcant.
Reintervention rates
Information about secondary interventions was available
for 83 of the 97 patients who had EVAR. There were nine
(11%) re-interventions (Table 2). Of these, eight were from
the 57 (14%) patients who were treated with custom-made
devices and one (2%) was on a patient treated with
commercially-made endograft.
Information was available for 61 of the 68 patients who
had open repair. There were eight (13%) interventions in
this group. Two patients developed supra-graft aneurysms,
of which one had an open thoraco-abdominal repair and
the other required a fenestrated EVAR. Four patients
required laparotomies for small bowel obstruction and two
patients had incisional hernia repairs.
DISCUSSION
This study demonstrates that the life expectancy of young
patients with AAA is poor, with nearly 40% of patients dying
within 6 years, mainly from non-aneurysm-related causes.
There were no differences in the long-term mortality rates
between patients who had custom-made EVAR and those
who had open repairs, despite the patients with open repair
generally being ﬁtter. However, with commercially available
endografts and better experience, there is a trend to better
outcomes in this EVAR group. The outcome from this young
group mirrors the outcome of the predominantly older
group of patients observed in the EVAR1 study and the UKFigure 2. KaplaneMeier survival analysis demonstrating cumula-
tive survival in the custom made endovascular aneurysm repair
(EVAR), commercially available EVAR, and the open abdominal
aortic aneurysm (AAA) repair groups.
Table 2. Re-intervention and associated mortality in patients who underwent endovascular aneurysm repair (EVAR).
Initial date
of EVAR
Type of
EVAR
Date of
re-intervention
Type of re-intervention Fatal outcome
January 1995 Custom January 2005 Open revision for migration Yes: perioperative
April 1996 Custom October 2009 Attempted embolisation of lumbars for
expanding sac
Yes: post-procedureddied
of rupture
May 1996 Custom October 1996 On-going type 1b endoleak requiring
open repair
No
August 1996 Custom November 2007 Occluded AUI requiring axillo-femoral
bypass
No
March 1997 Custom September 2000 Open revision for graft migration Yes: perioperative
February 1996 Custom July 2007 Expanding sac with type II endoleak
requiring embolisation of lumbar arteries
No
May 1999 Custom April 2007 Pseudoaneurysm at a the top end with
a type 1 endoleakdopen revision
Yes: perioperative
February 2000 Custom July 2003 Type 1b endoleak requiring further stent
graft
No
June 2003 Commercial March 2007 Occluded limb requiring femefem crossover
graft
No
Note. AUI ¼ aorto-uni-iliac.
318 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 3 September/2013small aneurysm study.4,10 The 30-day outcomes are also
similar to results from the National Surgical Quality
Improvement Program dataset, where patients under the
age of 60 years who were treated with EVAR were studied.7
In the Multicentre Aneurysm Screening Study (MASS),
approximately 11% of patients died within 4 years of their
aneurysm operation. Of these, a third died from cardio-
vascular causes (non-AAA-related) and a third died from
cancer.11 As aortic diameter increases, there is a corre-
sponding increase in non-AAA-related mortality, with the
majority of deaths caused by cardiovascular disease.12 A
recent study reported a 42% 2-year morality in patients
with AAAs of 4e5.4 cm.13
The results of the present study suggest that young pa-
tients with AAA may not have the same lifespan as an age-
matched population without AAA. As with the MASS study,
the majority of deaths in the presented study were not
related to EVAR, but were non-aneurysm-related with
myocardial infarctions and cancers responsible for the ma-
jority of the deaths. Perhaps the development of AAA at a
younger age is a marker for more aggressive vascular dis-
ease and a poorer survival rate.
One concern about EVAR in the young is the lifetime risk
of a secondary procedure because of a problem with the
implanted graft.4,5 The re-intervention rate in this study is
similar to that quoted in randomised trials.5 Nine of the ten
re-interventions were required in patients treated during
the development of endovascular devices with the use of
custom-made endografts. The use of ﬁrst-generation grafts
and early experience with EVAR are signiﬁcant factors that
have resulted in these complications. In addition, this sub-
group of patients had a longer follow up in which to
develop problems. New generation grafts have low re-
intervention rates.14,15 In this study, the majority of re-
interventions were performed with low morbidity and
mortality using endovascular methods.16 The two patients
who had late open conversion died, which highlights the
signiﬁcant mortality with this technique.14,17Type II endoleaks in the presence of an increase in
aneurysm sac size have also been associated with adverse
outcomes.18,19 There was one patient who, despite embo-
lisation of the lumbar artery and attempted embolisation of
the circumﬂex iliac artery, presented with a late rupture.
This occurred despite close surveillance, and highlights the
importance of aggressive management of patients with
expanding sacs in the presence of an endoleak.20
This study has several limitations. It was a non-
randomised retrospective analysis with the usual limita-
tions. There was a signiﬁcant loss of follow up; however, we
were able to ascertain the mode of death using a combi-
nation of hospital, general practice, and death certiﬁcate
records in this group of patients. The pathway of deciding
whether open repair or EVAR is offered to patients has
somewhat evolved over the course of the introduction of
EVAR. The use of custom-made ﬁrst-generation grafts and
the early experience of EVAR may explain the early mor-
tality and high late re-intervention rates in this study.15 All
the deaths that occurred within 30 days and 90% of the re-
intervention occurred in the group with custom-made
EVARs. AAA-related deaths may also be under-reported as
not all patients who died had post-mortems performed. In
addition, we did not have data about the proportion of
patients who were treated with best medical therapy and
the compliance of use during the duration of follow up.
EVAR is now being increasingly used as the primary mode
of treatment of AAA in patients, mainly owing to lower
perioperative mortality when compared with open repair.
Patients under the age of 65 years with an AAA do not
necessary have long lifespans. In the less ﬁt younger pa-
tients with AAA, the results with EVAR are comparable with
those ﬁt patients who had open AAA repair. The manage-
ment of ﬁtter young patients with AAA remains contro-
versial, but improving results with EVAR over time may
increase the role of EVAR in this group. A larger dataset and
longer follow up with re-intervention data will need to be
investigated to answer this controversial question.
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